SCOUP - Continuing Education Lesson - 05/13/08

New User? Register Here


CE Home \| Help
FAQs \| Minimum Requirements \| Contact Us

Insomnia Management in Long-Term Care: Challenges and Opportunities

Course Information

Back to Catalog

This lesson is supported by:

Takeda Pharmaceuticals North America, Inc.

Manju T Beier, PharmD, FASCP
Senior Partner
Geriatric Consultant Resources LLC
Clinical Associate Professor of Pharmacy
The University of Michigan
Ann Arbor, MI

Phyllis Zee, MD, PhD
Professor
Dept of Neurology
Northwestern University
Feinberg School of Medicine
Chicago, IL

Faculty Disclosure

Dr. Zee discloses that she has been a member of the speaker's bureau for Takeda Pharmaceuticals North America, Inc. and has participated in advisory committees for Boehringer Ingelheim Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., sanofi aventis, and Takeda Pharmaceuticals North America, Inc.

Dr. Beier has no relevant financial relationships to disclose.

Goals and Objectives

Insomnia is experienced by over 30% of the adult population at some point in time, and the prevalence of insomnia increases with age. The elderly are often viewed as difficult to treat, but they are among the patients with the greatest need for treatment. As the elderly population grows in this country and the number of long-term care (LTC) residents increases, healthcare professionals working in the LTC sector need to be properly educated on how to best diagnose and treat this common condition. Research indicates that the utilization rates of sleep agents in nursing homes vary dramatically from institution to institution. Hence, there does not appear to be a consistent practice pattern to help guide clinicians, underscoring the need for evidence-based education. This program will present practical strategies that outline how to evaluate and manage insomnia using pharmacologic and nonpharmacologic strategies. The presentation will also address which pharmacologic agents are most appropriate for those with multiple comorbidities.

Upon completion of this educational activity, the participant should be able to:
1. Discuss ways to recognize those who may be at risk for insomnia
2. Evaluate barriers that hinder proper diagnosis and management
3. Outline appropriate behavioral and pharmacologic strategies for treating insomnia in the long-term care setting
4. Summarize efficacy and safety data for pharmacologic agents approved for the treatment of chronic insomnia
5. Describe the impact of updates to the State Operations Manual on the management of insomnia in the long-term care facility

Target Audience

Pharmacists and other healthcare professionals

Technologies Used

Monograph

Price: FREE!

ACPE - Pharmacists Accreditation
	ASCP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This home study web activity has been assigned a maximum of 1 credit hours and the ACPE UPN: 203-999-07-076-H01-P. This accreditation expires on 03/14/2009.
	To receive educational credit, participants must complete an online evaluation form and pass the online assessment with a score of 70% or better. If you do not receive a minimum score of 70% or better, you are permitted 1 retake(s). After passing the assessment, you can view, print and track your statements of credit online. There is no fee to participate in this activity.

The material presented here does not reflect the views of Pharmacy Choice, Inc., RxSchool, or the companies providing educational content. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
This lesson is supported by: Takeda Pharmaceuticals North America, Inc.